Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

48 results about "Metabolic change" patented technology

Metabolic changes are the most common sign of aging within cells. This increases the risk of diseases such as type 2 diabetes, stroke, and hypertension. Insulin resistance is a major metabolic syndrome observed in older adults. This can lead to hepatic gluconeogenesis, adipose lipogenesis, defective glycogen synthesis, and glucose uptake.

Method of increasing yield of spinosad by improving fermentation condition of saccharopolyspora spinosa based on metabonomics

The invention discloses a method of increasing the yield of spinosad by improving the fermentation condition of saccharopolyspora spinosa based on metabonomics. The method comprises the following steps: (1) determining intracellular metabolite of the saccharopolyspora spinosa; (2) analyzing the capability of the saccharopolyspora spinosa of producing the spinosad; (3) carrying out PLS analysis; and (4) carrying out process analysis. According to the method disclosed by the invention, the metabolite change law in the process of producing the spinosad by virtue of fermentation of the saccharopolyspora spinosa is revealed by utilizing the metabonomics means and combining multivariate statistics, and a metabolic change mechanism related to production of the spinosad is further explained; by analyzing the spinosad production capability and the metabolic level of the saccharopolyspora spinosa in different growth environments, the metabolin related to the production of the spinosad is found, thus providing a direction for optimizing the culture process of the saccharopolyspora spinosa and increasing the fermentation yield of the spinosad. The invention also provides new thinking and method for study in other culture technological processes of producing macrolides microorganisms.
Owner:TIANJIN UNIV

Detection method for hydroxysafflor yellow A metabolic product

The invention discloses a detection method for hydroxysafflor yellow A metabolic products. The method includes the steps of: 1) performing intravenous injection to an SD rat with a safflower extract and aceglutamide injection, performing orbid blood sampling, and centrifugally separating the blood sample to obtain plasma; 2) sucking the plasma with a micro sample injector, adding acetonitrile with volume ratio of plasma to acetonitrile being 1:3-3.5, uniformly mixing the substances with vortex and centrifuging the mixture to obtain a supernatant, blow-drying the supernatant with nitrogen gas, dissolving the dried substance in acetonitrile, and centrifuging the solution to obtain a supernatant as a detection sample; and 3) detecting and analyzing the sample through high performance liquid chromatography-triple quadrupoles linear ion trap tandem mass spectrometry, and analyzing the metabolic products in a p-MRM-IDA-EPI mode. In the invention, a p-MRM method is employed in the mass spectrum with combination of Light Sight software to quickly identify and analyze the sample for tracing metabolic change of component change and structure change in the plasma; 11 hydroxysafflor yellow A metabolic products are found in the result. The method can be used for obtaining a time change curve of the hydroxysafflor yellow A and the metabolic product thereof in plasma, and successfully deduces and identifies the molecular structures of seven metabolic products and isomers of the hydroxysafflor yellow A. The method, compared with a chemical structure analytic method, is more quick and sensitive.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY

Method for real-time detection of monoamine neurotransmitter change in brains of animals under smoke exposure condition

A method for real-time detection of monoamine neurotransmitter change in brains of animals under a smoke exposure condition is characterized by exposing the animals to smoke in real time by adopting an animal oro-nasal inhalation smoke exposure system, collecting an animal brain tissue sample through an on-line microdialysis technique, and quickly analyzing monoamine neurotransmitters and metabolite thereof in a brain dialysate sample by using a high performance liquid chromatography/coularray detector, so as to detect monoamine neurotransmitter change characteristics in the brains of the animals before and after smoke exposure in real time. According to the method provided by the invention, exposure to the smoke of the animals is more similar to the manner of human beings smoking tobacco products, the technical difficulty of incapability of real-time simulating and evaluating of monoamine neurotransmitter change caused by smoke inhaling (nicotine intaking) is overcome, the method has the advantages of simple operation, accurate and reliable result and the like, and compared with the prior art, a new method for monitoring monoamine neurotransmitter metabolic change in the brains of the animals after smoke exposure is created.
Owner:ZHENGZHOU TOBACCO RES INST OF CNTC

Method for analysis of metabolite difference between two biological samples using gas chromatography-mass spectrometry

Disclosed is a method of extracting all metabolites existing in a biological sample to detect a comprehensive difference between metabolites of a control group and a test group, thereby verifying significance thereof. More particularly, the invention comprises a first step of analyzing a fraction extracted with a solid phase extraction method, a fraction obtained by extracting the remnant fraction with a liquid-liquid extraction method and fractions extracted with the liquid-liquid extraction method at two pH different from each other after the hydrolysis, with a gas chromatography-mass spectrometry; a second step of converting the chromatogram result into numerical values capable of being statistically processed; and a third step of analyzing the numerical values with a principal component analysis (PCA) and a discriminant analysis (DA) to detect a difference between the control group and the test group. According to the invention, the difference between the two groups can be comprehensively detected with the areas of the peaks on the chromatogram, without a standard material or verified quantitative method. Therefore, it is possible to detect the metabolic change in the organism due to the disease or gene mutation, without an accurate quantitative analysis of the metabolites.
Owner:KOREA INST OF SCI & TECH

Cold-coagulation-blood-stasis-syndrome-resistant differential metabolite metabolic pathway and study method of Chinese angelica-based cold-coagulation blood-stasis treatment decoction

The invention discloses a cold-coagulation-blood-stasis-syndrome-resistant differential metabolite metabolic pathway and study method of a Chinese angelica-based cold-coagulation blood-stasis treatment decoction. The method comprises: detecting and analyzing endogenous metabolites changed at different time points after cold-coagulation blood-stasis symptoms forming of a female rat under an ice-water bath and epinephrine induction and Chinese angelica-based cold-coagulation blood-stasis treatment decoction intervention by using an ultra-high performance liquid chromatography tandem mass spectrometry so as to obtain a fingerprint spectrum; with a multivariate variable statistical analysis method, carrying out screening from a plurality of variables and identifying 21 significantly changed metabolites; and enriching eight metabolic pathways related to different development stages of the cold-coagulation blood-stasis symptom by using ametaboanalyst open-source online metabonomics analysiswebsite. According to the invention, the related metabolic changes in the occurrence and development process of the old-coagulation blood-stasis symptoms and the treatment process of the Chinese angelica-based cold-coagulation blood-stasis treatment decoction are studied by using a dynamic analysis method; the disease occurrence and development mechanisms at different time points can be revealed;and the abnormal metabolic network regulated and controlled by medicines in the treatment process can be clarified.
Owner:GUANGXI MEDICAL UNIVERSITY

Screening method

The present invention provides a method of screening a mammal for the onset or predisposition to the onset of a neuropsychiatric disorder. More particularly, the present invention provides a method of screening a mammal for the onset or predisposition to the onset of schizophrenia by screening for a decrease in the functional level of protein 14-3-3ζ. In a related aspect, the present invention also provides a means of monitoring a patient diagnosed with a neuropsychiatric disorder, such as schizophrenia, by screening for changes to functional levels of protein 14-3-3ζ. This may be useful, for example, in the context of evaluating the effectiveness of a prophylactic or therapeutic treatment regime or otherwise monitoring the impact of physiological or metabolic changes which may occur in a patient. The method of the present invention is useful in a wide range of applications including, inter alia, providing a means of identifying mammals susceptible to the onset of a neuropsychiatric condition, such as a condition characterized by one or more symptoms of schizophrenia, thereby enabling the implementation of prophylactic or early therapeutic intervention in an effort to either minimize or prevent the onset of the condition. It also provides a means of confirming diagnoses which would otherwise be based solely on an assessment of positive and negative symptoms.
Owner:PRECISION MEDICINE HLDG PTY LTD

Liposomally encapsulated reduced glutathione for management of cancer, including with other pharmaceutical compositions

InactiveUS20150030668A1Promote recoveryIncreased myocardial tissue levelBiocidePeptide/protein ingredientsAbnormal tissue growthDisease
This invention proposes an agent to block the “fuel supply” that energizes cancer cell growth by protecting surrounding cells to the cancer, particularly stromal fibroblast cells. The invention disables the products of surrounding cells useable for energy conversion by the cancer cell thereby crippling the cell and disabling its growth process. This application describes the use of a formulation of liposomally encapsulated glutathione that is preferably used orally to increase the level of glutathione in tissues in order to prevent and reverse the metabolic changes in cells that results in the formation of the metabolic fuel that supports cancer cells and to prevent the oxidative stress that damages normal support cells such as fibroblasts and can prevent and reverse these cells from the steps of autophagy and mitophagy that results in the cells decreasing the normal mitochondrial production of ATP for energy and resorting to the use of aerobic glycolysis for energy production. The use of oral liposomally encapsulated glutathione will maintain the presence and normal function of caveolin in fibroblast and other cells, thus preventing their conversion to autophagic tumor stromal cells. By stopping the formation of autophagic cells, the production of the metabolic fuel needed by cancer cells is stopped, which results in the death of the cancer cells. Compositions using liposomally encapsulated glutathione and other compounds that enhance the favorable effects of liposomal glutathione on cancer disease are referenced.
Owner:GUILFORD FREDERICK TIMOTHY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products